SBIR Phase I: Development of arrays to record dynamic interactions between single cells

SBIR 第一阶段：开发记录单细胞之间动态相互作用的阵列

• 批准号: 2229323
• 负责人: Rebecca Berdeaux
• 金额: $ 27.5万
• 依托单位: CELLCHORUS INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2024-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2229323&HistoricalAwards=false
• 关键词: SBIR; Phase; Development; arrays; record

The broader/commercial impact of this Small Business Innovation Research (SBIR) Phase I project is to enable experts in the biomedical field to improve understanding of how new therapeutic approaches are developed and perform in the context of a complex immune system. This technology could enable new therapies to translate to patients faster, at less expense, and with higher rates of success. These therapeutics, such as antibodies, cell and gene therapies, and vaccines, can deliver excellent results when they work, but available therapies do not work for all patients. To develop and deliver the next generation of therapies to improve the lives of patients, investigators need to be able to understand how immune cells and other cells move, interact, kill, and survive over time. This project allows researchers, developers, and manufacturing experts to understand the functional performance of new therapies earlier, more completely, and at lower expense. Such single-cell analysis is a multi-billion market among commercial and non-profit markets.The proposed project will develop and rigorously validate a novel array consumable that enables scaling dynamic, single-cell analysis from an early access laboratory to any facility worldwide. Initial design and testing activities for the next generation arrays using non-scalable proof of concept production methodologies have demonstrated the value of the dynamic single-cell functional analysis platform. This project will develop and evaluate two options for producing the arrays, one with an embossing technique and one with a three-dimensional printing technique. Successful completion of this project will support scaling the only platform that can evaluate migration, contact dynamics, killing, survival, subcellular activity, and biomolecule secretion for the same individual cell over time and in high throughput to improve development and delivery of novel therapies faster, with higher rates of success, and at lower expense.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I阶段项目的更广泛/商业影响是使生物医学领域的专家能够在复杂的免疫系统的背景下发展对新的治疗方法的理解。这项技术可以使新疗法能够更快地转化为患者，费用较低，并且成功率更高。这些治疗剂，例如抗体，细胞和基因疗法以及疫苗，可以在工作时提供出色的效果，但可用的疗法对所有患者都不起作用。为了开发和交付下一代疗法以改善患者的生活，研究人员需要能够了解免疫细胞和其他细胞如何随着时间的流逝而移动，相互作用，杀死和生存。该项目使研究人员，开发人员和制造专家能够更早，更全部，更低的费用了解新疗法的功能性能。这种单细胞分析是商业和非营利市场中的数十亿个市场。拟议的项目将开发和严格验证可消耗的新型阵列，该阵列可以从早期访问实验室到全球任何设施，从而将动态的单细胞分析扩展。使用概念生产方法的不可估计证明的下一代阵列的初始设计和测试活动已证明了动态单细胞功能分析平台的价值。该项目将开发和评估生产阵列的两个选项，一个选项具有压花技术，另一种具有三维印刷技术。该项目的成功完成将支持缩放唯一可以评估迁移，接触动力学，杀戮，生存，亚细胞活动和生物分子分泌的平台，并且随着时间的流逝以及高吞吐量，以更快地改善新型疗法的开发和交付，该奖项反映了NSF的法定任务，并以较高的费用率提高了成功的速度，并且被认为是值得通过基金会的知识分子优点和更广泛的影响审查标准的评估来支持的。